Search research articles
Contact Us
Filters
Showing results (271-280 of 344) with videos related to
Page
of 35
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
March 13, 2021
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study
Wasat Mansoor, Hendrik-Tobias Arkenau, Maria Alsina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 9, 2022
Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
Hiroki Yukami, Akihito Kawazoe, Yi-Tzu Lin, et al.
Cancer Research Communications
|
July 12, 2023
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
Hanae Ida, Toshio Shimizu, Makoto Nishino, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
October 30, 2015
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
Kohei Shitara, Kei Muro, Yasuhiro Shimada, et al.
Therapeutic Advances in Medical Oncology
|
September 23, 2025
Impact of claudin 18.2 expression on treatment outcomes of first-line immunochemotherapy in patients with HER2-negative, proficient MMR, PD-L1 CPS ⩾1 metastatic gastric/gastroesophageal junction cancer
Fei Zhang, Izuma Nakayama, Naoya Sakamoto, et al.
Molecular Cancer
|
September 13, 2024
Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics
Sophie Cousin, Jean-Philippe Guégan, Kohei Shitara, et al.
Scientific Reports
|
January 12, 2021
Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens
Yukie Kashima, Yosuke Togashi, Shota Fukuoka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, et al.
Cancer Science
|
June 14, 2022
Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer
Kensei Yamaguchi, Keiko Minashi, Daisuke Sakai, et al.
The Lancet. Oncology
|
October 26, 2018
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
Kohei Shitara, Toshihiko Doi, Mikhail Dvorkin, et al.
Page
of 35
Search research articles
Search
Showing results (271-280 of 344) with videos related to
Sort By:
Page
of 35
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
March 13, 2021
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study
Wasat Mansoor, Hendrik-Tobias Arkenau, Maria Alsina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 9, 2022
Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
Hiroki Yukami, Akihito Kawazoe, Yi-Tzu Lin, et al.
Cancer Research Communications
|
July 12, 2023
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
Hanae Ida, Toshio Shimizu, Makoto Nishino, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
October 30, 2015
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
Kohei Shitara, Kei Muro, Yasuhiro Shimada, et al.
Therapeutic Advances in Medical Oncology
|
September 23, 2025
Impact of claudin 18.2 expression on treatment outcomes of first-line immunochemotherapy in patients with HER2-negative, proficient MMR, PD-L1 CPS ⩾1 metastatic gastric/gastroesophageal junction cancer
Fei Zhang, Izuma Nakayama, Naoya Sakamoto, et al.
Molecular Cancer
|
September 13, 2024
Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics
Sophie Cousin, Jean-Philippe Guégan, Kohei Shitara, et al.
Scientific Reports
|
January 12, 2021
Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens
Yukie Kashima, Yosuke Togashi, Shota Fukuoka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 4, 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials
Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, et al.
Cancer Science
|
June 14, 2022
Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer
Kensei Yamaguchi, Keiko Minashi, Daisuke Sakai, et al.
The Lancet. Oncology
|
October 26, 2018
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
Kohei Shitara, Toshihiko Doi, Mikhail Dvorkin, et al.
Page
of 35